Details

Autor(en) / Beteiligte

• Vail, Emily A
• Wunsch, Hannah
• Pinto, Ruxandra
• Bosch, Nicholas A
• Walkey, Allan J
• Lindenauer, Peter K
• Gershengorn, Hayley B

Titel

Use of Hydrocortisone, Ascorbic Acid, and Thiamine in Adults with Septic Shock

Ist Teil von

• American journal of respiratory and critical care medicine, 2020-12, Vol.202 (11), p.1531-1539

Ort / Verlag

United States: American Thoracic Society

Erscheinungsjahr

2020

Quelle

MEDLINE

Beschreibungen/Notizen

• In December 2016, a single-center study describing significant improvements in mortality among a small group of patients with severe sepsis and septic shock treated with hydrocortisone, high-dose ascorbic acid, and thiamine (HAT therapy) was published online. This study aims to describe the administration of HAT therapy among U.S. adults with septic shock before and after study publication and to compare outcomes between patients who received and did not receive HAT therapy. We performed a retrospective cohort study of 379 acute care hospitals in the Premier Healthcare Database including patients discharged from October 1, 2015, to September 30, 2018. Exposure was quarter year of hospital discharge; postpublication was defined as January 2017 onward (July 2017 for effectiveness analyses). The primary outcome was receipt of HAT at least once during hospitalization. We conducted unadjusted segmented regression analyses to examine temporal trends in HAT administration. In patients with early septic shock, we compared the association of early HAT therapy (within 2 d of hospitalization) with hospital mortality using multivariable modeling and propensity score matching. Among 338,597 patients, 3,574 (1.1%) received HAT therapy, 98.7% in the postpublication period. HAT administration increased from 0.03% of patients (95% confidence interval [CI], 0.02-0.04) before publication to 2.65% (95% CI, 2.46-2.83) in the last quarter, with a significant step up in use after December 2016 (  < 0.001). Receipt of early HAT was associated with higher hospital mortality (28.2% vs. 19.7%;  < 0.001; adjusted odds ratio, 1.17 [95% CI, 1.02-1.33]; primary propensity-matched model adjusted odds ratio, 1.19 [95% CI, 1.02-1.40]). Publication of a single-center retrospective study was associated with significantly increased administration of HAT. Among patients with early septic shock, receipt of HAT was not associated with mortality benefit.